Dexamethasone-induced posterior reversible encephalopathy syndrome.
Irvin
William
W
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
MacDonald
Gigi
G
Smith
J Keith
JK
Kim
William Y
WY
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000556:secondary; D003907:Dexamethasone / Q000009:adverse effects*; D018492:Dopamine Antagonists / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D020343:Hypertensive Encephalopathy / Q000139:chemically induced*; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007249:Inflammation / Q000517:prevention & control; D008175:Lung Neoplasms / Q000473:pathology; D008875:Middle Aged; D011725:Pyridines / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D014196:Trazodone / Q000627:therapeutic use; D000077334:Zolpidem
D000893:Anti-Inflammatory Agents; D003907:Dexamethasone; D018492:Dopamine Antagonists; D006220:Haloperidol; D006993:Hypnotics and Sedatives; D011725:Pyridines; D017367:Selective Serotonin Reuptake Inhibitors; D014196:Trazodone; D000077334:Zolpidem